Ardelyx Stock Climbs on Raised FY Revenue Outlook for IBS Treatment

Dow Jones

2025/10/31

By Kelly Cloonan

Shares of Ardelyx rose after the company raised its full-year revenue guidance for its irritable bowel syndrome treatment due to strong demand.

The stock climbed 22% to $6.11 on Friday. Shares are up 21% this year.

The company now expects revenue of $270 and $275 million for its Ibsrela treatment for the full year, up from $250 million to $260 million previously.

The updated outlook comes as Ibsrela continues to post strong growth due to sustained demand from IBS patients with constipation, the company said.

For the third quarter, the company posted a loss of $969,000, or 0 cents a share, compared with a loss of $809,000, or 0 cents a share, a year earlier. Analysts polled by FactSet had forecast a loss of 6 cents a share.

Revenue rose to $110.3 million compared with $98.2 million a year ago. Analysts had expected $100.5 million.

The growth was led by Ibsrela, up 92% to $78.2 million. Xphozah revenue declined to $27.4 million due to a loss of Medicare coverage, the company said.

Write to Kelly Cloonan at kelly.cloonan@wsj.com

(END) Dow Jones Newswires

October 31, 2025 11:53 ET (15:53 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2579982499"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2579982499\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2579982499?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-31 23:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2579982499","market":"sg","top_or_hot":-1,"title":"Ardelyx Stock Climbs on Raised FY Revenue Outlook for IBS Treatment","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/ARDX\">Ardelyx</a> rose after the company raised its full-year revenue guidance for its irritable bowel syndrome treatment due to strong demand. \n</p>\n<p>\n  The stock climbed 22% to $6.11 on Friday. Shares are up 21% this year. \n</p>\n<p>\n  The company now expects revenue of $270 and $275 million for its Ibsrela treatment for the full year, up from $250 million to $260 million previously. \n</p>\n<p>\n  The updated outlook comes as Ibsrela continues to post strong growth due to sustained demand from IBS patients with constipation, the company said. \n</p>\n<p>\n  For the third quarter, the company posted a loss of $969,000, or 0 cents a share, compared with a loss of $809,000, or 0 cents a share, a year earlier. Analysts polled by FactSet had forecast a loss of 6 cents a share. \n</p>\n<p>\n  Revenue rose to $110.3 million compared with $98.2 million a year ago. Analysts had expected $100.5 million. \n</p>\n<p>\n  The growth was led by Ibsrela, up 92% to $78.2 million. Xphozah revenue declined to $27.4 million due to a loss of Medicare coverage, the company said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 31, 2025 11:53 ET (15:53 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ardelyx Stock Climbs on Raised FY Revenue Outlook for IBS Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArdelyx Stock Climbs on Raised FY Revenue Outlook for IBS Treatment\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-10-31 23:53</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/ARDX\">Ardelyx</a> rose after the company raised its full-year revenue guidance for its irritable bowel syndrome treatment due to strong demand. \n</p>\n<p>\n  The stock climbed 22% to $6.11 on Friday. Shares are up 21% this year. \n</p>\n<p>\n  The company now expects revenue of $270 and $275 million for its Ibsrela treatment for the full year, up from $250 million to $260 million previously. \n</p>\n<p>\n  The updated outlook comes as Ibsrela continues to post strong growth due to sustained demand from IBS patients with constipation, the company said. \n</p>\n<p>\n  For the third quarter, the company posted a loss of $969,000, or 0 cents a share, compared with a loss of $809,000, or 0 cents a share, a year earlier. Analysts polled by FactSet had forecast a loss of 6 cents a share. \n</p>\n<p>\n  Revenue rose to $110.3 million compared with $98.2 million a year ago. Analysts had expected $100.5 million. \n</p>\n<p>\n  The growth was led by Ibsrela, up 92% to $78.2 million. Xphozah revenue declined to $27.4 million due to a loss of Medicare coverage, the company said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 31, 2025 11:53 ET (15:53 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ARDX","symbol_name":"Ardelyx","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2579982499","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2579982499","pubTimestamp":1761925980,"columns":[{"name":"行業數據","id":30,"label_key":"dataReport"}],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Ardelyx rose after the company raised its full-year revenue guidance for its irritable bowel syndrome treatment due to strong demand.The stock climbed 22% to $6.11 on Friday. Shares are up 21% this year.The company now expects revenue of $270 and $275 million for its Ibsrela treatment for the full year, up from $250 million to $260 million previously.The updated outlook comes as Ibsrela continues to post strong growth due to sustained demand from IBS patients with constipation, the company said.For the third quarter, the company posted a loss of $969,000, or 0 cents a share, compared with a loss of $809,000, or 0 cents a share, a year earlier. Analysts polled by FactSet had forecast a loss of 6 cents a share.Revenue rose to $110.3 million compared with $98.2 million a year ago. Analysts had expected $100.5 million.The growth was led by Ibsrela, up 92% to $78.2 million. Xphozah revenue declined to $27.4 million due to a loss of Medicare coverage, the company said.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"ARDX":"Ardelyx"},"translate_title":"Ardelyx股价因IBS治疗财年收入前景上调而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARDX":1.5},"content_text":"By Kelly Cloonan \n\n\n \n\n\n  Shares of Ardelyx rose after the company raised its full-year revenue guidance for its irritable bowel syndrome treatment due to strong demand. \n\n\n  The stock climbed 22% to $6.11 on Friday. Shares are up 21% this year. \n\n\n  The company now expects revenue of $270 and $275 million for its Ibsrela treatment for the full year, up from $250 million to $260 million previously. \n\n\n  The updated outlook comes as Ibsrela continues to post strong growth due to sustained demand from IBS patients with constipation, the company said. \n\n\n  For the third quarter, the company posted a loss of $969,000, or 0 cents a share, compared with a loss of $809,000, or 0 cents a share, a year earlier. Analysts polled by FactSet had forecast a loss of 6 cents a share. \n\n\n  Revenue rose to $110.3 million compared with $98.2 million a year ago. Analysts had expected $100.5 million. \n\n\n  The growth was led by Ibsrela, up 92% to $78.2 million. Xphozah revenue declined to $27.4 million due to a loss of Medicare coverage, the company said. \n\n\n \n\n\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 31, 2025 11:53 ET (15:53 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}